Molefy Pharma is a Spanish biotech company created in 2024 from a collaboration between ARQUIMEA and the CSIC, with the aim of developing innovative therapies for ALS and other neurodegenerative diseases.
ARQUIMEA is the majority investor and provides technological capabilities, business vision, and experience in industrial scale-up.
The CSIC contributes scientific excellence, cutting-edge research in molecular biology, and the patents that underpin our therapeutic candidates.
The combination of both drives a unique model of applied innovation.
Our lead project is AP-2, a molecule designed to regulate TDP-43, halt the progression of ALS, and reverse cellular dysfunction. We are also developing AP-3, aimed at frontotemporal dementia.
AP-2 has already completed preclinical development and is currently being evaluated by the AEMPs in order to obtain approval to begin the clinical phase.
AP-3 has shown promising results in animal models and is progressing toward regulatory studies.
We have both public and private funding. Notable contributors include the ALS Association, which is funding the clinical trial, and the Alzheimer’s Drug Discovery Foundation, which is funding part of AP-3’s preclinical work.
We are currently seeking non-dilutive funding in Europe and the United States. For Phase II, we will launch an active investment round and are open to collaborations with institutional investors, venture capital funds, and strategic partners committed to biomedical innovation.
In our News & Publications section you will find scientific advances, publications, and corporate updates. You can also subscribe to receive our latest news.